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Abstract 
Background: The total atrial conduction time can be measured as the time from the onset of 
the P wave on the ECG to the peak of the A wave recorded at the mitral annulus using tissue 
Doppler imaging (A´; P-A´TDI); when prolonged, it might predict incident atrial fibrillation 
(AF).  
Methods: We measured P-A´TDI in outpatients with heart failure (HF) and sinus rhythm 
enrolled in the SICA-HF programme. 
Results: P-A´TDI measured at the lateral mitral annulus was longer in patients with HF with 
reduced (LVEF<50%, N=141; 126 (112-146 ms); P=0.005) or preserved left ventricular 
ejection fraction (LVEF>50% and NT-proBNP>125 ng/l, N=71; 128 (108-145) ms compared 
to controls (N = 117; 120 ms (106-135); P=0.026). Increasing age, left atrial volume and PR 
interval were independently associated with prolonged P-A´TDI. 
During a median follow up of 1251 (956 - 1602) days, 73 patients with HF died (N=42) or 
developed AF (N=31). In univariable analysis, P-A´TDI was associated with an increased risk 
of the composite outcome of death or AF, but only increasing log [NT-proBNP], age and 
more severe symptoms (NYHA III vs I/II) were independently related to this outcome. 
Patients in whom both P-A´TDI and left atrial (LA) volume were above the median (127 ms 
and 64 ml, respectively) had the highest incidence of AF (HR: 6.61 95% CI: 2.27-19.31; 
P<0.001 compared to those with both P-A´TDI and LA volume below the median). 
Conclusions: Measuring P-A´TDI interval identifies patients with chronic HF at higher risk of 
dying or developing AF during follow-up.  
Keywords: atrial fibrillation, PA-TDI, heart failure, echocardiography, SICA-HF. 
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Introduction 
Atrial fibrillation (AF) and heart failure (HF) often coexist: in registries and clinical trials the 
prevalence of AF in patients with HF ranges between 15% to 50%, depending on HF severity 
and phenotype (1). Incident AF might precipitate symptoms and negatively impact on costs, 
morbidity and mortality of patients with HF (2); however, in many cases, AF coincides with, 
or precedes, the development of HF itself, perhaps making clinically evident an 
asymptomatic, or undiagnosed cardiac condition. The identification of patients at high risk of 
developing AF might lead to strategies to prevent and target interventions (3). Many risk 
scores have been studied and validated to predict incident AF in the community, but similar 
models are lacking for patients with heart failure (4).  Evaluating atrial structure and function 
by imaging might be a useful tool to identify patients with HF at higher risk of developing 
AF (5, 6).  
The total atrial conduction time is a measure of the length of time between the initiation of 
atrial depolarisation and the peak of atrial mechanical activity. It can be measured as the 
interval between the onset of the P wave on the ECG to the peak of the A wave recorded at 
the mitral annulus using tissue Doppler imaging (A´; P-A´TDI). Increasing P-A´TDI predicts 
incident atrial fibrillation in the general population (7), in patients suffering a myocardial 
infarction or a cryptogenic stroke (8, 9), and in those who have had radiofrequency catheter 
ablation for atrial fibrillation (10). It might also be a simple and useful method for identifying 
patients with severe HF at risk of developing AF (11). We studied the clinical associations 
and the predictive role of P-A´TDI measured in ambulatory patients with a broad range of HF 
severity.  
Methods 
Study Population  
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Between October 2010 and March 2014, 711 control subjects and patients with heart failure 
were enrolled in Kingston-Upon-Hull, UK, for the Studies Investigating Co-morbidities 
Aggravating Heart Failure (SICA-HF, ClinicalTrials.gov Identifier: NCT01872299)(12). 
SICA-HF is an international observational study of the prevalence, incidence and impact of 
key co-morbidities in ambulatory patients with a clinical diagnosis of HF. For the purpose of 
this analysis, we considered patients to have heart failure if they had signs or symptoms and 
confirmed evidence of cardiac dysfunction, either reduced left ventricular ejection fraction on 
echocardiography (LVEF <50%, HFrEF) or abnormal NT-proBNP (>125 ng/L; heart failure 
with preserved LVEF, HFpEF)(13). Patients with end-stage renal failure or on renal dialysis, 
an alternative cause for raised NT-proBNP, were not enrolled in the study. Subjects who were 
paced or in atrial fibrillation at baseline were excluded from the current analysis. 
Patients were managed according to contemporary guidelines and were assessed after their 
medical therapy was optimised. Patients provided a detailed clinical history and had blood 
tests (including haematology, biochemistry profile and NT-proBNP), ECGs and 
echocardiograms done on the same day.  
Controls were subjects aged >60 years who had no history of heart failure, who were 
recruited to the SICA-HF study by invitation from primary care practice lists. Because of the 
design and focus of the trial, a substantial proportion of the control population had to be at a 
high risk of developing HF and had a clinical diagnosis of type 2 diabetes or hypertension, or 
both; however, they were included only if they were asymptomatic, had normal left 
ventricular function on echocardiography, and an NT-proBNP< 400 ng/L.  
The investigation conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent.  
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Outcome 
This is a retrospective study, but the primary outcome of interest was decided a priori to be 
the time to the composite of all-cause mortality and incidence of atrial fibrillation. We also 
considered all-cause mortality and incident atrial fibrillation separately as secondary 
outcomes.  
Our hospital is the only one in the region offering acute medical services. We have access to 
both primary and secondary care records. Outcome is censored at the point of last medical 
contact in primary or secondary care. Data regarding deaths and incident AF were collected 
from the hospital’s electronic systems, supplemented by information from patients, discharge 
letters and their family doctors. Only episodes of AF documented by treating clinicians or 
other health care providers in discharge letters, follow-up ECGs, hospital electronic records, 
and correspondence, which might include results of 24h tape, were included. We did not 
specifically investigate for incident atrial fibrillation, unless clinically indicated, and did not 
distinguish between permanent or paroxysmal episodes of AF.  All data regarding admissions 
and deaths were entered into a dedicated online database, and were adjudicated at regular 
intervals by different researchers blind to any other measurement collected at the time of the 
clinical visit. 
 
Echocardiographic measurements 
Echocardiography was performed by an experienced operator using a Vivid Seven (GE 
Health care, UK) system operating at 1.7-3.4MHz. Doppler tracings and two-dimensional 
images were obtained from parasternal long- and short- axis, apical and subcostal views. 
Echocardiograms were stored and reviewed by an experienced operator (AB) blinded to other 
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patient details using an EchoPAC station (GE Health care, UK). LVEF was measured using 
Simpson’s biplane method. Maximal (LA max) and minimal (LA min) left atrial volumes 
were measured in the four chamber view, and left atrial emptying fraction was calculated 
accordingly ((LA max-LA min/LA max)*100). Tricuspid annular plane systolic excursion 
(TAPSE) was used to assess right ventricular (RV) systolic function. The maximum trans-
tricuspid systolic velocity was also measured by echocardiography.  
 
P-A´TDI interval 
Of the 711 patients and controls, 499 (70%) were in sinus rhythm. P-A´TDI interval was 
retrospectively measured from stored echocardiograms (by VN) in only 329 (70%) of them, 
with the exclusions chiefly due to a poor ECG trace with low voltage P wave (n=100, figure 
1 supplementary).  
P-A´TDI was measured from the beginning of the P wave at the ECG trace to the peak of the 
A wave (A’) obtained by placing the TDI sampling volume at both the lateral and septal 
mitral annulus (lateral and septal P-A´TDI interval). P-A´TDI interval was measured in three 
consecutive heart cycles, and their average value was used for the analysis.  
 
Statistical methods 
Categorical data are presented as number and percentages; normally distributed continuous 
data as mean + SD and non-normally distributed continuous variables as median and 
interquartile range. 
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25 patients were randomly selected and medial and lateral P-A´TDI were measured 
separately by two operators blind to each other’s results (VN and SD). The inter- and 
intra-operator reproducibility of the P-A´TDI measurements were tested using Bland-
Altman plots. 
 
Because lateral P-A´TDI interval was more closely related to the primary endpoint in 
univariable analysis than medial P-A´TDI interval, we decided to group patients with HF by 
terciles of lateral P-A´TDI interval to illustrate the relation between P-A´TDI  and outcome. 
Patients in tercile 1 were those with the shortest lateral P-A´TDI interval.  
One-way ANOVA and Kruskal-Wallis tests were used to compare continuous variables 
between groups depending on the normality of the distribution, and the chi-squared test was 
used for categorical variables.  
Simple and multiple linear regression models were used to identify variables associated 
with lateral and septal P-A´TDI interval. Only variables that were significantly 
associated with P-A´TDI in univariable analysis (p<0.1) were entered into the 
multivariable analysis.  
Univariable and multivariable Cox proportional hazard regression models were used to 
investigate the relationship of clinical, biochemical and echocardiographic variables with 
outcome. Given the low number of events, different multivariable models were tested by 
choosing, prospectively, clinical, biochemical or echocardiographic variables of interest in 
addition to lateral P-A´TDI interval to prevent overfitting. 
Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. 
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All analyses were performed using SPSS (v.22) software. A 2-sided p-value < 0.05 was 
considered statistically significant. 
 
Results 
Patient characteristics 
Of the 329 patients, 212 had HF (of whom 141 had HFrEF and 71 HFpEF) and there were 
117 controls. The mean (± standard deviation) age of patients with HF (n=212) was 70+11 
years, 24% were women, 72% had IHD; mean LVEF was 44±13% and median plasma NT-
proBNP was 482 (IQR: 254 –1204) ng/l. Their demographic, clinical and echocardiographic 
characteristics are reported in table 1 and table 1 supplementary. Nearly 90% of those with 
HFrEF were receiving a beta-blocker and an ACE-I (or ARB), and >50% an MRA. Amongst 
control subjects, 85% had diabetes (DM), 78% had a clinical history of hypertension (HTN) 
and 12% had history of IHD. Their mean age was 70+10, 52% were men; their mean LVEF 
was 61+6% and median NT-proBNP was 90 (44 -157) ng/l. 
 
P-A´TDI measurements 
Reproducibility of measurements of P-A´TDI was good (intra-operator reproducibility: septal 
P-A´TDI mean difference = 1.9 (95% limits of agreement: -23.5 - 27.4) ms with 3 values 
outside limits of agreement (12%); lateral P-A´TDI mean difference = 4.8 (95% limits of 
agreement: -23.7 – 33.3) ms with 2 values outside limits of agreement (8%); inter-operator 
reproducibility: septal P-A´TDI mean difference = 0.7 (95% limits of agreement: -32.7 – 34.1) 
ms with 2 values outside limits of agreement (8%); lateral P-A´TDI mean difference = 2.1 
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(95% limits of agreement: -30.0 – 34.1) ms with 1 value outside limits of agreement (4%)) 
(figure 2 supplementary). 
 
Patients with heart failure, either HFpEF or HFrEF, had a longer lateral P-A´TDI interval than 
controls; patients with HFrEF had the longest septal P-A´TDI interval, which was, however, 
similar between patients with HFpEF and controls.  
 
Compared to those with HF in the lowest tercile of lateral P-A´TDI interval (shorter interval), 
those in the highest tercile were older, had more severe symptoms, higher NT-proBNP and 
creatinine plasma levels, and longer PR interval at ECG. Other than a more dilated left atrium 
in the highest P-A´TDI interval tercile, there were no echocardiographic differences between 
the three terciles (Table 1).   
 
Increasing septal and lateral P-A´TDI correlated with increasing log [creatinine] and log 
plasma [NT-proBNP]. Increasing lateral P-A´TDI also correlated with increasing QRS 
interval and decreasing heart rate (table 2 supplementary). P-A´TDI interval, either measured 
at lateral or septal mitral annulus, was longer in patients with IHD, but there was no 
association between other clinical variables (sex, presence of diabetes, mitral or tricuspid 
regurgitation, or clinical signs of congestion) and P-A´TDI (table 3 supplementary). There 
was no relation between P-A´TDI and measures of LV dimension or systolic function and 
measurements of diastolic function expressed as E/E’ ratio. 
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In patients with HF, increasing age, PR interval and LA volume were independently 
associated with increasing lateral P-A´TDI interval (Table 2 supplementary) (overall 
R2=0.12); only decreasing body mass index and increasing left atrial volume were 
independently associated with increasing septal P-A´TDI interval (R2=0.18). 
 
Outcome   
There were 82 primary outcome events during the median follow up of 1251 (IQ range: 956 - 
1602) days. The first qualifying event was incident AF in 4 controls and 31 patients and 
death in 5 controls and 42 patients.  
 
Patients in the highest tercile of lateral P-A´TDI had a much higher risk of death or incident 
AF than those in the lowest (lateral P-A´TDI: HR 2.52, 95% CI: 1.42 – 4.46; p=0.002) (Figure 
1). Patients in the highest tercile of lateral P-A´TDI had a much higher risk of incident AF 
than those in the lowest (HR 5.86, 95% CI: 1.98 – 17.15; p=0.001) but the risk of death was 
similar (HR: 1.68, 95% CI: 0.86-3.31; p=0.13). 
 
For those patients in whom either lateral P-A´TDI or LA volume were above the median (127 
ms for lateral P-A´TDI, 64 ml for LA volume), the risk of  incident AF was similar to those 
who had both lateral P-A´TDI interval and LA volume below the median; patients in whom 
both lateral P-A´TDI interval and LA volume were above the median had the highest 
incidence of AF (HR: 6.61 95% CI:2.27-19.31; P<0.001 compared to those with lateral P-
A´TDI interval and LA volume below the median, figure 2). There were too few events 
amongst the control population to be able to establish any relation between P-A´TDI and risk.  
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In univariable Cox regression analysis (Table 4 supplementary), both lateral and septal P-
A´TDI were associated with an increased risk of events. Increasing lateral P-A´TDI  was 
significantly related to an increase in the risk of the primary outcome either in patients with 
LVEF <50% (HR: 1.01 (95% CI: 1.00-1.02), X2 : 5.1, p=0.024) or in those with LVEF>50% 
(HR: 1.03 (95% CI: 1.01-1.04), X2 : 9.5, p=0.002). However, it did not predict outcome when 
analysis was restricted to those with an LVEF <40% (HR:1.01 (95% CI: 1.00-1.02), X2 : 3.6, 
p=0.056). In multivariable analysis, increasing log [NT-proBNP], age and more severe 
symptoms (NYHA IIIvsI/II) were the only variables independently related to an adverse 
outcome in the different models we tested. Lateral P-A´TDI interval entered these models 
only when the strongest variables associated with outcome were removed (table 2).  
 
Discussion 
We have found that an increased total atrial conduction time measured by tissue Doppler 
imaging amongst patients with heart failure in sinus rhythm is associated with higher NT-
proBNP plasma levels and a higher risk of developing atrial fibrillation, particularly when a 
prolonged lateral P-A´TDI interval is associated with a dilated left atrium.   
AF is the most common arrhythmia in patients with HF. Although the consequences of AF 
are to reduce quality of life, and to increase mortality, its pathophysiology is not completely 
understood. Indeed, left atrial enlargement and impaired function, reflecting the long term 
consequences of a stiff and dysfunctional LV leading to increased LA pressure, are only part 
of the factors contributing to AF development. Atrial stretch might enhance production of 
natriuretic peptides, but also trigger arrhythmias (14) and increase fibrosis.  Aging, oxidative 
stress and neurohormonal activation might further contribute to the development of atrial 
fibrosis, which further predisposes to, or maintains, AF (15). Atrial wall fibrosis might also 
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increase inter-atrial conduction time and enhance the risk of developing AF (16-18). A 
prolonged P-A´TDI interval might thus be a marker of electrical and structural atrial 
remodelling and reflect the combined effects on atrial conduction of a dilated left atrium 
(which increases conduction time from the sinoatrial node to the atrioventricular node) and 
fibrosis (which slows conduction velocity) (19, 20). 
We found that lateral P-A´TDI was longer than the septal, and differentiated between different 
populations with or without HF, regardless of LVEF. The difference between lateral and 
septal P-A´TDI may be due to the difference in conduction distances. The distance between 
the sinoatrial node (SAN) and the lateral side of left atrium is greater than the distance 
between the SAN and the medial side of left atrium. Thus electrical and structural atrial 
remodelling is likely to have a greater effect on lateral, rather than septal, P-A´TDI.  
Our findings are in agreement with previous studies conducted amongst patients with cardiac 
dysfunction in different settings. Antoni and colleagues (8) studied P-A´TDI interval 
measured within 48 hours following an acute myocardial infarction in 613 patients in sinus 
rhythm, many of whom had systolic dysfunction (mean LVEF 46%). They found that left 
atrial volume and P-A´TDI were independent predictors of incident AF during 12 months 
follow-up; P-A´TDI interval also improved model prediction if added  to clinical (age, 
troponin levels, PR interval) and echocardiographic (mitral regurgitation and left atrial 
volume) variables. In another study, Bertini and colleagues (11) studied 495 patients with 
severe heart failure, in sinus rhythm, who had an ICD implanted for primary or secondary 
prevention, many of whom (97%) also received a CRT device. They found that P-A´TDI (as 
well as female sex and history of AF) was an independent predictor of incident AF during 
follow-up. Our study confirms and extends these findings to patients with HF and a broad 
range of left ventricular ejection fraction and HF severity.  
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Our findings also confirm the role of well-known risk factors for incident AF, such as 
advanced age or severe symptoms. Our findings also support the emerging notion that raised 
circulating levels of natriuretic peptides plasma levels are powerful predictors of incident AF, 
at least amongst those patients with a reduced LVEF (3, 21).  
 
Study limitations 
Our study has several limitations. It was a retrospective study and it was not possible to 
analyse 30% of the stored echocardiograms, mainly because the ECG trace was not optimized 
for timing measurements. Prospective studies are needed to validate these data and their 
possible clinical implications. Although the patient population enrolled in the present study 
was relatively large, the number of events was small. The incidence of AF in our patients was 
in agreement with previous studies (incidence of AF at 12 months: 5%), and higher to that 
which we have previously reported (3); however, is still possible that short runs of AF, or 
prolonged asymptomatic episodes, were undetected.  
 
More than 25% of our control group had natriuretic peptides plasma levels between 125-400 
ng/l, probably reflecting subtle cardiac dysfunction and high cardiovascular risk (22). 
Although they were asymptomatic and the vast majority was free of clinical congestion, some 
were treated with loop diuretic and, had they been breathless, would have fulfilled our criteria 
for a diagnosis of HFpEF, a difficult diagnosis to make (22-24). Moreover, many of the 
controls suffered from hypertension and/or type II diabetes, two common comorbidities that 
might increase the risk of heart failure (22), atrial fibrillation and prolong the P-A´TDI 
interval (25): is possible that P-A´TDI interval might be shorter in individuals who are entirely 
free of cardiovascular risk factors. In those without HF, those with DM had a longer lateral, 
but not septal, P-A´TDI interval than those without DM (septal P-A´TDI: DM – 99 (21) ms, no 
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DM: 90 (18) ms, p=0.078; lateral P-A´TDI: DM – 121 (22) ms, no DM: 109 (22) ms, 
p=0.026). We did not find any differences between those with or without hypertension. Only 
5 controls were free of cardiovascular risk factors.   
 
Conclusion 
P-A´TDI is a simple novel echocardiographic variable which identifies patients with HF at 
higher risk of developing atrial fibrillation. 
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Legend to figures 
 
Figure 1. Kaplan Meier curves for the primary outcome of death from all causes and incident 
AF. Comparing the highest (HF-T3, yellow line) and lowest (HF-T1, purple line) terciles of 
P-A´TDI interval for patients with HF, those in the highest tercile had a much higher risk of 
death or incident AF. Those in the highest tercile of P-A´TDI interval had a >7 fold risk of this 
outcome than those considered without HF (No-HF).  
Figure 2. Risk of incident AF according to left atrial size and lateral P-A´TDI. For those 
patients with either lateral P-A´TDI interval or LA volume above the median (127 ms for 
lateral P-A´TDI, 64 ml for LA volume) the risk of  incident AF was similar to those who had 
both lateral P-A´TDI interval and LA volume below the median; patients in whom both lateral 
P-A´TDI interval and LA volume were above the median had the highest incidence of AF 
(HR: 6.61 95% CI:2.27-19.31; P<0.001 compared to those with lateral P-A´TDI interval and 
LA volume below the median). 
Figure 1 supplementary. Consort diagram showing the disposition of patients enrolled. Of 
499 patients in sinus rhythm, 100 had a poor ECG trace and for another 38 the quality, or 
absence, of the images limited the analysis. 32 patients with paced rhythm were not enrolled 
in the study. Of the remaining 329, 212 patients had HF and 117 were controls.  
Figure 2 supplementary. The inter- (right panel) and intra-operator (left panel) 
reproducibility of the P-A´TDI measurements tested using Bland-Altman plots is shown. 
 
 
Variable Missing  Controls 
N=117 
HF 
P-A´TDI lateral 
Tercile 1 
N=71 
HF 
P-A´TDI lateral 
Tercile 2 
N=71 
HF 
P-A´TDI lateral 
Tercile 3 
N=70 
 
P amongst  
P-A´TDI terciles 
P-A´TDI 
P-A´TDI septal –ms 0 100 (87-112) 86 (74-95) 107 (96-116) 125 (117-140) NA 
P-A´TDI lateral – ms 0 120 (106-135) 105 (94-111) 127 (124-131) 151 (145-161) NA 
P-A´TDI lat-sep – ms 0 21 (14) 17 (14) 22 (14) 28 (18) <0.001 
Demographics 
Age – years 0 70 (10) 69 (12) 68 (12) 73 (7) 0.004 
Sex (male) – no. (%) 0 61 (52) 50 (70) 50 (70) 52 (74) 0.84 
Waist circumference – cm 6 102 (14) 101 (17) 102 (15) 103 (13) 0.70 
Hip circumference - cm 12 109 (11) 105 (15) 109 (14) 108 (10) 0.26 
BMI- kg/m2 0 31 (6) 30 (6) 30 (7) 30 (5) 0.75 
BSA - m2 0 1.93 (0.26) 1.91 (0.23) 1.96 (0.22) 1.95 (0.21) 0.37 
SBP – mmHg 0 144 (20) 132 (29) 133 (21) 128 (23) 0.50 
DBP – mmHg 0 75 (11) 73 (14) 72 (11) 70 (12) 0.41 
DM – no. (%) 0 99 (85) 33 (47) 35 (49) 23 (33) 0.11 
Hypertension – no. (%) 0 91 (78) 46 (65) 56 (79) 51 (73) 0.17 
IHD – no. (%) 0 14 (12) 45 (63) 45 (63) 55 (79) 0.08 
Paroxysmal AF – no. (%) 0 0 (0) 1 (1) 5 (7) 5 (7) 0.21 
Crackles – no. (%) 3 0 (0) 1 (1) 5 (7) 3 (4) 0.26 
Raised Jugular vein– no. (%) 3 1 (1) 6 (9) 8 (11) 9 (13) 0.73 
Peripheral oedema > ankles no. (%) 3 6 (5) 8 (12) 11 (16) 9 (13) 0.79 
NYHA Class I – no. (%) 0  
NA 
20 (28) 23 (32) 15 (21)  
0.011 NYHA Class II – no. (%) 0 40 (56) 45 (63) 37 (53) 
NYHA Class III – no. (%) 0 11 (16) 3 (4) 18 (26) 
Blood test 
NTproBNP – ng/L 0 90 (44-157) 401 (219-896) 429 (241-848) 764 (332-1735) 0.005 
Albumin – g/l 0 40 (3) 39 (3) 39 (4) 39 (4) 0.57 
Creatinine-umol/L 0 78 (67-98) 95 (77-124) 99 (77-132) 109 (88-147) 0.040 
Haemoglobin – g/dl 0 13.5 (1.4) 13.1 (1.5) 13.5 (1.7) 13.1 (1.7) 0.35 
ECG 
Heart rate – bpm 0 73 (13) 67 (12) 65 (11) 64 (10) 0.34 
PR interval – ms 0 164 (31) 173 (37) 180 (32) 196 (37) 0.001 
QRS interval – ms 2 86 (80-96) 98 (88-118) 102 (92-118) 108 (92-141) 0.12 
Echocardiography 
LVEDD - cm 0 4.7 (0.6) 5.5 (0.7) 5.7 (0.9) 5.6 (0.9) 0.49 
LVEDV – ml 0 95 (28) 136 (47) 143 (55) 142 (64) 0.67 
LVEF - % 0 61 (6) 44 (12) 44 (12) 45 (13) 0.75 
LA diameter - cm 0 3.6 (0.5) 3.7 (0.5) 3.9 (0.6) 4.1 (0.6) <0.001 
LA volume - ml 2 52 (18) 56 (20) 63 (25) 74 (24) <0.001 
LAEF - % 0 62 (12) 51 (13) 52 (14) 49 (14) 0.52 
E/E’ lat 0 8.7 (2.9) 10.4 (5.3) 11.4 (6.3) 11.8 (7.5) 0.44 
E/E’ sep 4 10.8 (3.9) 14.4 (8.9) 14.0 (7.3) 15.6 (7.9) 0.49 
TAPSE – mm 4 22 (3) 19 (4) 20 (5) 20 (4) 0.25 
Tricuspid velocity – m/s 111 2.3 (0.4) 2.4 (0.5) 2.5 (0.5) 2.5 (0.5) 0.63 
MR – mild 0 27 (23) 30 (42) 39 (55) 33 (47) 
0.43 
MR > mild 0 0 (0) 11 (16) 5 (7) 7 (10) 
TR – mild 0 21 (18) 24 (34) 22 (31) 20 (29) 
0.66 
TR > mild 0 2 (2) 2 (3) 2 (3) 5 (7) 
Medications 
ACE-I or ARB- no. (%) 0 64 (55) 60 (85) 65 (92) 59 (84) 0.35 
Beta-blockers- no. (%) 0 27 (23) 59 (83) 60 (85) 58 (83) 0.96 
MRA - no. (%) 0 4 (3) 30 (42) 27 (38) 33 (47) 0.55 
Loop diuretic - no. (%) 0 7 (6) 31 (44) 32 (45) 43 (61) 0.06 
Digoxin - no. (%) 0 2 (2) 2 (3) 2 (3) 7 (10) 0.032 
 
Table 1: Baseline characteristics of patients with HF divided by terciles of lateral P-A´TDI interval and controls. List of abbreviation used: P-
A´TDI – Time between the beginning of the P wave on ECG and the peak of A’ wave measured by tissue Doppler imaging at the septal or lateral 
mitral annulus; HF – Heart Failure; BMI – Body Mass Index; BSA – Body Surface Area; SBP - Systolic Blood Pressure; DBP - Diastolic Blood 
Pressure; DM – Diabetes Mellitus; IHD - Ischemic Heart Disease; AF – Atrial Fibrillation; NYHA – New York Heart Association; NTproBNP - 
N-terminal B-type Natriuretic Peptide; LVEDD – Left Ventricle End Diastolic Diameter; LVEDV – Left Ventricle End Diastolic Volume; 
LVEF - Left Ventricle Ejection Fraction; LA - Left Atrium; LAEF – Left Atrium Ejection Fraction; TAPSE – Tricuspid Annulus Plane Systolic 
Excursion; MR – Mitral Regurgitation; TR – Tricuspid Regurgitation; ACE-I – Ace-Inhibitors; ARB – Angiotensin Receptor Blockers; MRA- 
mineralocorticoid Receptor Antagonist; NA – Not Applicable. 
Clinical model 1 Full model 
HR (95% CI); p 
Log(NT-proBNP)  removed 
HR (95% CI); p 
Log(NT-proBNP) &  Age removed 
HR (95% CI); p 
Age – years 1.04 (1.01-1.06); 0.016 1.05 (1.02-1.08); 0.002 - 
Log(NT-proBNP)   3.68 (1.94-7.01);<0.001 - - 
Creatinine – umol/l  1.01 (1.00-1.01);0.002 1.01 (1.00-1.01);<0.001 
P-A´TDI lateral - ms   1.01 (1.00-1.02); 0.011 
DBP – mmHg   0.98 (0.96-1.00); 0.017 
E/e’septal    
LA volume - ml    
Clinical model 2 Full model 
HR (95% CI); p 
Log(NT-proBNP)  removed 
HR (95% CI); p 
Log(NT-proBNP)  & NYHA removed  
HR (95% CI); p 
Age – years 1.04 (1.01-1.07); 0.012 1.05 (1.02-1.08); 0.002 1.05 (1.02-1.08); <0.001 
Log(NT-proBNP)   2.80 (1.53-5.14);0.001 - - 
Creatinine – umol/l   1.01 (1.00-1.01);0.010 
P-A´TDI lateral - ms  1.01 (1.00-1.02); 0.042 1.01 (1.00-1.02); 0.048 
NYHA III vs I/II 1.86 (1.06-3.26);0.030 2.52 (1.51-4.20);<0.001 - 
Peripheral 
oedema>ankles 
   
LA volume - ml    
Clinical model 3 Full model 
HR (95% CI); p 
Log(NT-proBNP)  removed 
HR (95% CI); p 
Log(NT-proBNP)  & NYHA removed 
HR (95% CI); p 
Age – years 1.04 (1.01-1.07); 0.009 1.05 (1.02-1.08); 0.001 1.06 (1.03-1.09);<0.001 
Log(NT-proBNP)   2.89 (1.64-5.11);<0.001 - - 
NYHA III vs I/II 1.82 (1.03-3.22);0.038 2.62 (1.57-4.38);<0.001 - 
P-A´TDI lateral - ms    
QRS – ms    
PR interval – ms    
LA volume - ml    
 
Table 2. Variables predictors of a combined outcome of AF or all-cause mortality in patients with heart failure only. Hazard ratios (HRs) have 
only been reported for variables that entered the multivariable models tested with a P<0.05. List of abbreviation used: NTproBNP - N-terminal 
B-type Natriuretic Peptide; P-A´TDI lateral - Time between the beginning of the P wave on ECG and the peak of A’ wave measured by tissue 
Doppler imaging at the lateral mitral annulus; DBP - Diastolic Blood Pressure; LA – Left Atrium; NYHA – New York Heart Association. 
 


